Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06729853 · ClinicalTrials.gov registry record · Phase 1
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
A Phase 1 study of Gout and Hyperuricemia, sponsored by Shanton Pharma Pte..
- Active
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT06729853: Active Phase 1 study of Gout and Hyperuricemia, sponsored by Shanton Pharma Pte..
NCT06729853 is a Phase 1 study of Gout and Hyperuricemia that is active but no longer recruiting, run by Shanton Pharma Pte.. The registered enrollment target is 32 participants, below the 8,887-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06729853, a Phase 1 study of Gout and Hyperuricemia, is active but no longer recruiting, sponsored by Shanton Pharma Pte..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multicenter, open-label, non-randomized, parallel-group, single-dose, 2-part, adaptive study in which up to approximately 32 adult subjects will be enrolled in one of 4 groups (8 subjects per group) with varying degrees of renal function.
Primary Outcome
The primary PK endpoints
Conditions Studied
Interventions
- DRUG SAP-001
Study Locations (2)
Florida
- Genesis Clinical Research - Tampa
Minnesota
- Nucleus Network Pty Ltd - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-04-24 |
| Est. Completion | 2025-04-28 |
| Phase | Phase 1 |
What the registry record for NCT06729853 still lists
NCT06729853 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 8,887-participant average among 34 other Gout trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Gout appearing as the primary indexed condition, and to 1 intervention - of which SAP-001 is the first listed.
NCT06729853 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06729853 about?
NCT06729853 is a clinical study titled "PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function". This is a multicenter, open-label, non-randomized, parallel-group, single-dose, 2-part, adaptive study in which up to approximately 32 adult subjects will be enrolled in one of 4 groups (8 subjects per group) with varying degrees of renal function.
What is the current status of trial NCT06729853?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-04-24. Estimated completion is 2025-04-28.
What conditions does trial NCT06729853 study?
This clinical trial studies the following conditions: Gout, Hyperuricemia.
What interventions are being tested in trial NCT06729853?
The interventions under investigation include: SAP-001 (DRUG).
Who is sponsoring clinical trial NCT06729853?
This trial is sponsored by Shanton Pharma Pte., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06729853 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06729853's enrollment target sits among peer trials
32 23rd of 34 higher than 12 of 34 other Gout trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
-
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
COMPLETED · Phase 1
-
Mild, Moderate and Severe Renal Impairment Study
COMPLETED · Phase 1
-
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
COMPLETED · Phase 1
-
NSAID Drug Interaction Study
COMPLETED · Phase 1
-
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI